- Virtual
Principled Engineering: AI and Drug Development
Where
Virtual
When
{{getUserDateTimeZone("1646265600").singleDate}}
{{getUserDateTimeZone("1646265600").time}} - {{getUserDateTimeZone("1646269200").time}} {{getClientTimeZoneName()}}
About
The use of artificial intelligence in drug discovery, when coupled with new genetic insights and the increase of patient medical data of the last decade, has the potential to bring novel medicines to patients more efficiently and more predictably. Join us for a discussion of the promise and potential pitfalls of relying on AI in bringing life-saving drugs to market — and an exploration of questions of justice and equity in drug research and access.
Our speakers will be Russ Altman, Stanford professor of bioengineering, genetics, medicine, and biomedical data science, in conversation with Kim Branson, global head of AI and machine learning at GSK. Jack Fuchs, an adjunct lecturer who teaches “Principled Entrepreneurial Decisions” at Stanford School of Engineering, will moderate and explore how clearly articulated principles can guide the direction of technological advancements like AI-enabled drug discovery.
View the live stream information for this event here
More events in "Biotech"
STAT heads to the west coast to explore the innovations changing health care as we know it. Unlock two full days of conversation exploring w…
The biggest names in health and science, all in one (virtual) place. Sign up to receive an alert when we launch tickets – STAT+ subscr…
Come for two days of silo-breaking and solution-focused discussions on the most important topics in health care with some of the industry
